NCT04403243View on ClinicalTrials.gov

COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

July 22, 2020

Study Completion Date

August 23, 2020

Conditions
COVID 19
Interventions
DRUG

Colchicine

0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.

DRUG

Ruxolitinib 5 MG

Ruxolitinib - 5mg twice a day per os for ten days

DRUG

Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]

Secukinumab - 300mg subcutaneously singly

OTHER

standard therapy

standard therapy for COVID 19

Trial Locations (1)

119620

Lomonosov Moscow State University Medical Research and Educational Center, Moscow

All Listed Sponsors
lead

Lomonosov Moscow State University Medical Research and Educational Center

OTHER

NCT04403243 - COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 | Biotech Hunter | Biotech Hunter